BAQSIMI 3 mg pdr appl nasale
7680674650010
CH-67465
H04AA01
07.06.3.
Reimbursement limitations:
BAQSIMI
Le remboursement est limité à un maximum de 2 boîtes de Baqsimi sur une période …
1 / 2
google
Details
- Product number
- 6746501
- CPT
- -
- Packaging group
- 1
- Unit
- Stück
- Composition
- glucagonum 3 mg, betadexum, dodecylphosphocholinum, ad pulverem.
Articles (1)
Baqsimi, Nasenpulver
Nasenpulver
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
3.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 61.90
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/10/2022
Authorization holder
Future Health Pharma GmbH
8620 Wetzikon ZH
Authorization information
- Swissmedic authorization number
- 67465
- Drug name
- Baqsimi, Nasenpulver
- Galenic form
- NASP
- ATC Code
- H04AA01
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 11/06/2020
- Authorization expiration date
- 31/12/9999
- IT number
- 07.06.3.
- Domain
- Human medicine
Packaging details
- Description (FR)
- BAQSIMI 3 mg pdr appl nasale
- Description (DE)
- BAQSIMI 3 mg Pulv zur nasal Anwendung
- Market launch
- 11/06/2020
- Narcotic (BTM)
- No